• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer.
【24h】

Preclinical Evaluation of Fever-Range, Whole Body Hyperthermia as an Adjuvant to Chemotherapy and Cytokine Immunotherapy for the Treatment of Breast Cancer.

机译：临床前评估发热范围，全身热疗作为化疗和细胞因子免疫治疗的辅助治疗乳腺癌。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This predoctoral grant was written to examine the effect of combining fever-range whole body hyperthermia with cytokine immunotherapy and chemotherapy in animal models of breast cancer. Progress in year number two has recently improved with the implementation of a new animal model that closely represents human breast cancer and will replace the less appropriate CT26 model (a colon cancer model) used in year number one. This represents the most significant advance. The 4T1 cell line is a murine mammary adenocarcinoma syngenic to balb/c mice that spontaneously metastasizes. Although only preliminary experiments have been performed suggesting that IL-l2 decreases lung metastasis, the model is now solidly in place in the laboratory. Secondly, the work with the CT26 model has moved forward slightly and the importance of IFN-gamma to the observed enhancement of the anti-tumor response with the combination of IL-l2 and whole body hyperthermia noted in year one has been hypothesized. Unfortunately, a bizarre, septic shock-like syndrome has been observed that has hampered further progress in both animal models the past 4 months. The etiology of this syndrome is still under investigation by the PI and the Roswell Park Cancer Institute Department of Laboratory Animal veterinary staff.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号